Gut microbiota dysbiosis has been repeatedly observed in obesity and type 2 diabetes mellitus, two metabolic diseases strongly intertwined with non-alcoholic fatty liver disease (NAFLD). Animal studies have demonstrated a potential causal role of gut microbiota in NAFLD. Human studies have started to describe microbiota alterations in NAFLD and have found a few consistent microbiome signatures discriminating healthy individuals from those with NAFLD, non-alcoholic steatohepatitis or cirrhosis. However, patients with NAFLD often present with obesity and/or insulin resistance and type 2 diabetes mellitus, and these metabolic confounding factors for dysbiosis have not always been considered. Patients with different NAFLD severity stages often present with heterogeneous lesions and variable demographic characteristics (including age, sex and ethnicity), which are known to affect the gut microbiome and have been overlooked in most studies. Finally, multiple gut microbiome sequencing tools and NAFLD diagnostic methods have been used across studies that could account for discrepant microbiome signatures. This Review provides a broad insight into microbiome signatures for human NAFLD and explores issues with disentangling these signatures from underlying metabolic disorders. More advanced metagenomics and multi-omics studies using system biology approaches are needed to improve microbiome biomarkers.
Whereas animal studies have demonstrated a potential causal role of gut microbiota in non-alcoholic fatty liver disease (NAFLD), human studies have only just started to describe microbiome signatures in NAFLD.
Proteobacteria are consistently enriched in steatosis and non-alcoholic steatohepatitis.
The invasion of oral bacteria (such as Prevotella or Veillonella) into the distal intestine is observed in cirrhosis.
Faecalibacterium prausnitzii abundance is reduced in cirrhosis and other diseases, including diabetes, obesity and irritable bowel syndrome.
Bacterial signatures (Clostridium and Lactobacillus) overlap between NAFLD and metabolic diseases (type 2 diabetes mellitus).
Discrepant microbiome signatures across studies could be linked to the heterogeneity of geographical regions, ethnicity, population characteristics, microbiome sequencing tools, NAFLD diagnostic tools, disease spectrum, drug consumption and circadian rhythm.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Signal Transduction and Targeted Therapy Open Access 27 September 2022
Gut virome profiling identifies a widespread bacteriophage family associated with metabolic syndrome
Nature Communications Open Access 23 June 2022
Gut microbiota and fermentation-derived branched chain hydroxy acids mediate health benefits of yogurt consumption in obese mice
Nature Communications Open Access 15 March 2022
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $6.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Fouhy, F., Ross, R. P., Fitzgerald, G. F., Stanton, C. & Cotter, P. D. Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of high-throughput sequencing to address these gaps. Gut Microbes 3, 203–220 (2012).
Prakash, S., Tomaro-Duchesneau, C., Saha, S. & Cantor, A. The gut microbiota and human health with an emphasis on the use of microencapsulated bacterial cells. J. Biomed. Biotechnol. 2011, 981214 (2011).
Fraher, M. H., O’Toole, P. W. & Quigley, E. M. M. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat. Rev. Gastroenterol. Hepatol. 9, 312–322 (2012).
Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
Li, J. et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 32, 834–841 (2014).
Karlsson, F., Tremaroli, V., Nielsen, J. & Bäckhed, F. Assessing the human gut microbiota in metabolic diseases. Diabetes 62, 3341–3349 (2013).
Lynch, S. V. & Pedersen, O. The human intestinal microbiome in health and disease. N. Engl. J. Med. 375, 2369–2379 (2016).
Bäckhed, F. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718–15723 (2004).
Ridaura, V. K. et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 341, 1241214 (2013).
Cani, P. D. et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470–1481 (2008).
Le Chatelier, E. et al. Richness of human gut microbiome correlates with metabolic markers. Nature 500, 541 (2013).
Cotillard, A. et al. Dietary intervention impact on gut microbial gene richness. Nature 500, 585–588 (2013).
Moreno-Indias, I., Cardona, F., Tinahones, F. J. & Queipo-Ortuño, M. I. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front. Microbiol. 5, 190 (2014).
Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55–60 (2012).
Karlsson, F. H. et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 498, 99–103 (2013).
Tilg, H., Zmora, N., Adolph, T. E. & Elinav, E. The intestinal microbiota fuelling metabolic inflammation. Nat. Rev. Immunol. 20, 40–54 (2020).
Aron-Wisnewsky, J. & Clément, K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat. Rev. Nephrol. 12, 169–181 (2016).
Plovier, H. et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat. Med. 23, 107–113 (2017).
Dewulf, E. M. et al. Insight into the prebiotic concept: lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 62, 1112–1121 (2013).
Davis, C. D. The gut microbiome and its role in obesity. Nutr. Today 51, 167–174 (2016).
Vrieze, A. et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143, 913–916.e7 (2012).
Kootte, R. S. et al. Improvement of insulin sensitivity after lean donor feces in metabolic syndrome is driven by baseline intestinal microbiota composition. Cell Metab. 26, 611–619 (2017).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59, 1121–1140 (2016).
Estes, C., Razavi, H., Loomba, R., Younossi, Z. & Sanyal, A. J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 67, 123–133 (2018).
Noureddin, M. et al. NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances. Am. J. Gastroenterol. 113, 1649–1659 (2018).
Castera, L. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: non-invasive tests are enough. Liver Int. 38 (Suppl. 1), 67–70 (2018).
Van Herck, M. A., Vonghia, L. & Francque, S. M. Animal models of nonalcoholic fatty liver disease-a starter’s guide. Nutrients 9, 1072 (2017).
Aron-Wisnewsky, J., Gaborit, B., Dutour, A. & Clement, K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin. Microbiol. Infect. 19, 338–348 (2013).
Wieland, A., Frank, D. N., Harnke, B. & Bambha, K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment. Pharmacol. Ther. 42, 1051–1063 (2015).
Roychowdhury, S., Selvakumar, P. C. & Cresci, G. A. The role of the gut microbiome in nonalcoholic fatty liver disease. Med. Sci. 6, 47 (2018).
Bedossa, P. et al. Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. Hepatology 56, 1751–1759 (2012). This work proposes a novel algorithm to classify patients as without NAFLD, with NAFLD or with overt NASH that is more robust than previous algorithms; since its development, it has been used in many studies.
Brunt, E. M. et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53, 810–820 (2011).
Hagström, H. et al. SAF score and mortality in NAFLD after up to 41 years of follow-up. Scand. J. Gastroenterol. 52, 87–91 (2017).
Pais, R. et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. J. Hepatol. 59, 550–556 (2013).
Schuppan, D. & Afdhal, N. H. Liver cirrhosis. Lancet 371, 838–851 (2008).
Fingas, C. D., Best, J., Sowa, J.-P. & Canbay, A. Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma. Clin. Liver Dis. 8, 119–122 (2016).
Ratziu, V., Bellentani, S., Cortez-Pinto, H., Day, C. & Marchesini, G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53, 372–384 (2010).
Karlas, T., Wiegand, J. & Berg, T. Gastrointestinal complications of obesity: non-alcoholic fatty liver disease (NAFLD) and its sequelae. Best. Pract. Res. Clin. Endocrinol. Metab. 27, 195–208 (2013).
Nusrat, S., Khan, M. S., Fazili, J. & Madhoun, M. F. Cirrhosis and its complications: evidence based treatment. World J. Gastroenterol. 20, 5442–5460 (2014).
Lu, Z.-Y., Shao, Z., Li, Y.-L., Wulasihan, M. & Chen, X.-H. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: an 8-year follow-up study. World J. Gastroenterol. 22, 3663–3669 (2016).
Fazel, Y., Koenig, A. B., Sayiner, M., Goodman, Z. D. & Younossi, Z. M. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 65, 1017–1025 (2016).
Wong, V. W.-S. et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J. Hepatol. 69, 1349–1356 (2018).
Ching-Yeung, Yu, B., Kwok, D. & Wong, V. W. Magnitude of nonalcoholic fatty liver disease: eastern perspective. J. Clin. Exp. Hepatol. 9, 491–496 (2019).
Yki-Järvinen, H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2, 901–910 (2014).
European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) & European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388–1402 (2016).
Vanni, E. et al. From the metabolic syndrome to NAFLD or vice versa? Digestive Liver Dis. 42, 320–330 (2010).
Yki-Järvinen, H. & Luukkonen, P. K. Diabetes, liver cancer and cirrhosis: what next? Hepatology 68, 1220–1222 (2018).
Younossi, Z. M. et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality. Hepatology 53, 1874–1882 (2011).
Sumida, Y., Nakajima, A. & Itoh, Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J. Gastroenterol. 20, 475–485 (2014).
Shen, J. et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J. Hepatol. 56, 1363–1370 (2012).
Dasarathy, S. et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J. Hepatol. 51, 1061–1067 (2009).
Wildman-Tobriner, B. et al. Association between magnetic resonance imaging-proton density fat fraction and liver histology features in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis. Gastroenterology 155, 1428–1435.e2 (2018).
Friedrich-Rust, M., Poynard, T. & Castera, L. Critical comparison of elastography methods to assess chronic liver disease. Nat. Rev. Gastroenterol. Hepatol. 13, 402–411 (2016).
Xiao, G. et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 66, 1486–1501 (2017).
Wong, V. W.-S. et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51, 454–462 (2010).
Papagianni, M., Sofogianni, A. & Tziomalos, K. Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World J. Hepatol. 7, 638–648 (2015).
Dyson, J. K., Anstee, Q. M. & McPherson, S. Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol. 5, 211 (2014).
Morra, R. et al. FibroMAXTM: towards a new universal biomarker of liver disease? Expert. Rev. Mol. Diagnostics 7, 481–490 (2007).
Alkhouri, N. et al. Evaluation of circulating markers of hepatic apoptosis and inflammation in obese children with and without obstructive sleep apnea. Sleep. Med. 16, 1031–1035 (2015).
Gunn, N. T. & Shiffman, M. L. The use of liver biopsy in nonalcoholic fatty liver disease: when to biopsy and in whom. Clin. Liver Dis. 22, 109–119 (2018).
Vilar-Gomez, E. & Chalasani, N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J. Hepatol. 68, 305–315 (2018).
Eddowes, P. J. et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology 156, 1717–1730 (2019).
Henao-Mejia, J. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179–185 (2012).
Le Roy, T. et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 62, 1787–1794 (2013).
Farrell, G. et al. Mouse models of nonalcoholic steatohepatitis Towards optimization of their relevance to human NASH. Hepatology 69, 2241–2257 (2019).
Nguyen, T. L. A., Vieira-Silva, S., Liston, A. & Raes, J. How informative is the mouse for human gut microbiota research? Dis. Model. Mech. 8, 1–16 (2015).
Chiu, C.-C. et al. Nonalcoholic fatty liver disease is exacerbated in high-fat diet-fed gnotobiotic mice by colonization with the gut microbiota from patients with nonalcoholic steatohepatitis. Nutrients 9, 1220 (2017).
Le Roy, T. et al. Comparative evaluation of microbiota engraftment following fecal microbiota transfer in mice models: age, kinetic and microbial status matter. Front. Microbiol. 9, 3289 (2018).
Hoyles, L. et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women. Nat. Med. 24, 1070–1080 (2018). This work reveals molecular networks linking the gut microbiome (using metagenomic analysis) and the host phenome (hepatic transcriptome as well as urine and plasma metabolome) to hepatic steatosis.
Brandl, K. & Schnabl, B. Intestinal microbiota and nonalcoholic steatohepatitis. Curr. Opin. Gastroenterol. 33, 128–133 (2017).
Leung, C., Rivera, L., Furness, J. B. & Angus, P. W. The role of the gut microbiota in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 13, 412–425 (2016).
Loomba, R. Role of imaging-based biomarkers in NAFLD: recent advances in clinical application and future research directions. J. Hepatol. 68, 296–304 (2018).
Wang, B. et al. Altered fecal microbiota correlates with liver biochemistry in nonobese patients with non-alcoholic fatty liver disease. Sci. Rep. 6, 32002 (2016).
Shen, F. et al. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat. Dis. Int. 16, 375–381 (2017). This work was one of the first to use the HiSeq 2000 platform to sequence the microbiome and discover a microbial related signature of NAFLD (biopsy proven) as compared with healthy individuals as controls in a Chinese cohort.
Raman, M. et al. Fecal microbiome and volatile organic compound metabolome in obese humans with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 11, 868–875.e1-3 (2013).
Loomba, R. et al. Gut microbiome based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease. Cell Metab. 25, 1054–1062.e5 (2017). This work offers a first microbiota signature of NAFLD-related fibrosis severity using whole-genome shotgun sequencing to sequence the microbiome in patients with biopsy-proven NASH and fibrosis.
Zhu, L. et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology 57, 601–609 (2013).
Del Chierico, F. et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. Hepatology 65, 451–464 (2017). This work provides a microbial signature of NAFLD–NASH in children and uses several control groups (one of individuals with obesity without NAFLD and one of healthy individuals).
Boursier, J. et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 63, 764–775 (2016).
Mouzaki, M. et al. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology 58, 120–127 (2013).
Michail, S. et al. Altered gut microbial energy and metabolism in children with non-alcoholic fatty liver disease. FEMS Microbiol. Ecol. 91, 1–9 (2015).
Da Silva, H. E. et al. Nonalcoholic fatty liver disease is associated with dysbiosis independent of body mass index and insulin resistance. Sci. Rep. 8, 1466 (2018).
Wong, V. W. et al. Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis–a longitudinal study. PLOS ONE 8, e62885 (2013).
Aron-Wisnewsky, J. et al. Major microbiota dysbiosis in severe obesity: fate after bariatric surgery. Gut https://doi.org/10.1136/gutjnl-2018-316103 (2018).
Pedersen, H. K. et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature 535, 376–381 (2016).
Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262–266 (2015).
Chen, Y. et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 54, 562–572 (2011).
Chen, Y. et al. Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Sci. Rep. 6, 34055 (2016).
Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60, 940–947 (2014). This paper discusses the gut microbial signature of patients with cirrhosis compared with that of healthy individuals, then addresses whether this signature is stable over time in compensated cirrhosis as well as further assessing the changes in patients undergoing decompensated cirrhosis.
Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59–64 (2014). The first study to offer a microbial signature of liver cirrhosis in adults, comparing 98 patients with 83 healthy individuals using quantitative metagenomics.
Caussy, C. et al. A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease. Nat. Commun. 10, 1406 (2019).
Iebba, V. et al. Combining amplicon sequencing and metabolomics in cirrhotic patients highlights distinctive microbiota features involved in bacterial translocation, systemic inflammation and hepatic encephalopathy. Sci. Rep. 8, 8210 (2018).
Cani, P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007).
Mao, J.-W. et al. Intestinal mucosal barrier dysfunction participates in the progress of nonalcoholic fatty liver disease. Int. J. Clin. Exp. Pathol. 8, 3648–3658 (2015).
Quévrain, E. et al. Identification of an anti-inflammatory protein from Faecalibacterium prausnitzii, a commensal bacterium deficient in Crohn’s disease. Gut 65, 415–425 (2016).
Sokol, H. et al. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm. Bowel Dis. 15, 1183–1189 (2009).
Rajilic´-Stojanovic´, M. et al. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology 141, 1792–1801 (2011).
Furet, J.-P. et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 59, 3049–3057 (2010).
Sharpton, S. R., Ajmera, V. & Loomba, R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin. Gastroenterol. Hepatol. 17, 296–306 (2019).
Harte, A. L. et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. 7, 15 (2010).
Arab, J. P., Karpen, S. J., Dawson, P. A., Arrese, M. & Trauner, M. Bile acids and nonalcoholic fatty liver disease: molecular insights and therapeutic perspectives. Hepatology 65, 350–362 (2017).
Cruz-Ramón, V., Chinchilla-López, P., Ramírez-Pérez, O. & Méndez-Sánchez, N. Bile acids in nonalcoholic fatty liver disease: new concepts and therapeutic advances. Ann. Hepatol. 16, S58–S67 (2017).
Chiang, J. Y. L. Bile acid metabolism and signaling in liver disease and therapy. Liver Res. 1, 3–9 (2017).
Canfora, E. E., Jocken, J. W. & Blaak, E. E. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11, 577–591 (2015).
Schwiertz, A. et al. Microbiota and SCFA in lean and overweight healthy subjects. Obesity 18, 190–195 (2010).
Raubenheimer, P. J., Nyirenda, M. J. & Walker, B. R. A choline-deficient diet exacerbates fatty liver but attenuates insulin resistance and glucose intolerance in mice fed a high-fat diet. Diabetes 55, 2015 (2006).
Yu, D. et al. Higher dietary choline intake is associated with lower risk of nonalcoholic fatty liver in normal-weight Chinese women. J. Nutr. 144, 2034–2040 (2014).
Spencer, M. D. et al. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology 140, 976–986 (2011).
Dumas, M.-E. et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl Acad. Sci. USA 103, 12511–12516 (2006).
Chen, Y. et al. Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults. Sci. Rep. 6, 19076 (2016).
Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
Tang, W. H. W. et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368, 1575–1584 (2013).
Koeth, R. A. et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19, 576–585 (2013).
Dumas, M.-E., Kinross, J. & Nicholson, J. K. Metabolic phenotyping and systems biology approaches to understanding metabolic syndrome and fatty liver disease. Gastroenterology 146, 46–62 (2014).
Di Ciaula, A. et al. Bile acid physiology. Ann. Hepatol. 16 (Suppl. 1), S4–S14 (2017).
Wahlström, A., Sayin, S. I., Marschall, H.-U. & Bäckhed, F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 24, 41–50 (2016).
Sayin, S. I. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 17, 225–235 (2013).
Staley, C., Weingarden, A. R., Khoruts, A. & Sadowsky, M. J. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl. Microbiol. Biotechnol. 101, 47–64 (2017).
Ridlon, J. M., Kang, D. J., Hylemon, P. B. & Bajaj, J. S. Bile acids and the gut microbiome. Curr. Opin. Gastroenterol. 30, 332–338 (2014).
Liu, H., Hu, C., Zhang, X. & Jia, W. Role of gut microbiota, bile acids and their cross-talk in the effects of bariatric surgery on obesity and type 2 diabetes. J. Diabetes Investig. 9, 13–20 (2018).
Kakiyama, G. et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J. Hepatol. 58, 949–955 (2013).
Chávez-Talavera, O., Tailleux, A., Lefebvre, P. & Staels, B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology 152, 1679–1694.e3 (2017).
Caussy, C. et al. Link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD. Hepatology https://doi.org/10.1002/hep.29892 (2018).
Volynets, V. et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Digestive Dis. Sci. 57, 1932–1941 (2012).
Bashiardes, S., Shapiro, H., Rozin, S., Shibolet, O. & Elinav, E. Non-alcoholic fatty liver and the gut microbiota. Mol. Metab. 5, 782–794 (2016).
Yuan, J. et al. Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 30, 675–688.e7 (2019).
Kolodziejczyk, A. A., Zheng, D., Shibolet, O. & Elinav, E. The role of the microbiome in NAFLD and NASH. EMBO Mol. Med. 11, e9302 (2019).
Chu, H., Duan, Y., Yang, L. & Schnabl, B. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease. Gut 68, 359–370 (2019).
Brown, A. J. et al. The Orphan G protein-coupled receptors GPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278, 11312–11319 (2003).
Samuel, B. S. et al. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl Acad. Sci. USA 105, 16767–16772 (2008).
den Besten, G. et al. Gut-derived short-chain fatty acids are vividly assimilated into host carbohydrates and lipids. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G900–G910 (2013).
Rau, M. et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol. J. 6, 1496–1507 (2018).
Rau, M. et al. Progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis is marked by a higher frequency of Th17 cells in the liver and an increased Th17/resting regulatory T cell ratio in peripheral blood and in the Liver. J. Immunol. 196, 97–105 (2016).
Sun, M., Wu, W., Liu, Z. & Cong, Y. Microbiota metabolite short chain fatty acids, GPCR, and inflammatory bowel diseases. J. Gastroenterol. 52, 1–8 (2017).
Maslowski, K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).
Wen, W. & Schwabe, R. F. Soluble fibers improve metabolic syndrome but may cause liver disease and hepatocellular carcinoma. Hepatology 70, 739–741 (2019).
Singh, V. et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell 175, 679–694 (2018).
Aron-Wisnewsky, J., Warmbrunn, M., Nieuwdorp, M. & Clément, K. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? Gastroenterology https://doi.org/10.1053/j.gastro.2020.01.049 (2020).
Kim, M. et al. Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing’s syndrome. Korean J. Physiol. Pharmacol. 22, 23–33 (2018).
Loomba, R., Sirlin, C. B., Schwimmer, J. B. & Lavine, J. E. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 50, 1282–1293 (2009).
Nobili, V. et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat. Rev. Gastroenterol. Hepatol. 16, 517–530 (2019).
Vos, M. B. et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J. Pediatr. Gastroenterol. Nutr. 64, 319–334 (2017).
Deschasaux, M. et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat. Med. 24, 1526–1531 (2018).
Bambha, K. et al. Ethnicity and nonalcoholic fatty liver disease. Hepatology 55, 769–780 (2012).
Gangarapu, V., Yildiz, K., Ince, A. T. & Baysal, B. Role of gut microbiota: obesity and NAFLD. Turk. J. Gastroenterol. 25, 133–140 (2014).
Ley, R. E., Turnbaugh, P. J., Klein, S. & Gordon, J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).
Jie, Z. et al. The gut microbiome in atherosclerotic cardiovascular disease. Nat. Commun. 8, 845 (2017).
Karlsson, C. L. J. et al. The microbiota of the gut in preschool children with normal and excessive body weight. Obesity 20, 2257–2261 (2012).
Tilg, H., Moschen, A. R. & Roden, M. NAFLD and diabetes mellitus. Nat. Rev. Gastroenterol. Hepatol. 14, 32–42 (2017).
Loomba, R. et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology 56, 943–951 (2012).
Larsen, N. et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5, e9085 (2010).
Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560–564 (2016).
Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555, 623–628 (2018).
Rhee, E. J. Nonalcoholic fatty liver disease and diabetes: an epidemiological perspective. Endocrinol. Metab. 34, 226–233 (2019).
Lonardo, A., Ballestri, S., Marchesini, G., Angulo, P. & Loria, P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig. Liver Dis. 47, 181–190 (2015).
Wu, H. et al. Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug. Nat. Med. 23, 850–858 (2017). The first study to decipher the effect of metformin on the gut microbiota signature in a randomized control trial, including individuals with drug-naive T2DM, using metagenomic analysis and gut stimulator experiments with faecal transfer in germ-free mice.
Shin, N.-R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014).
Depommier, C. et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat. Med. 25, 1096–1103 (2019).
Dao, M. C. et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: relationship with gut microbiome richness and ecology. Gut 65, 426–436 (2016).
Pastori, D. et al. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig. Liver Dis. 47, 4–11 (2015).
Caparrós-Martín, J. A. et al. Statin therapy causes gut dysbiosis in mice through a PXR-dependent mechanism. Microbiome 5, 95 (2017).
Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740–748 (2016).
Yeh, M. M. & Brunt, E. M. Pathology of nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 128, 837–847 (2007).
Koch, L. K. & Yeh, M. M. Nonalcoholic fatty liver disease (NAFLD): diagnosis, pitfalls, and staging. Ann. Diagn. Pathol. 37, 83–90 (2018).
Reinke, H. & Asher, G. Circadian clock control of liver metabolic functions. Gastroenterology 150, 574–580 (2016).
Parsons, M. J. et al. Social jetlag, obesity and metabolic disorder: investigation in a cohort study. Int. J. Obes. 39, 842–848 (2015).
Asher, G. & Sassone-Corsi, P. Time for food: the intimate interplay between nutrition, metabolism, and the circadian clock. Cell 161, 84–92 (2015).
Archer, S. N. et al. Mistimed sleep disrupts circadian regulation of the human transcriptome. Proc. Natl Acad. Sci. USA 111, E682–E691 (2014).
Thaiss, C. A. et al. Microbiota diurnal rhythmicity programs host transcriptome oscillations. Cell 167, 1495–1510 (2016).
Thaiss, C. A. et al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell 159, 514–529 (2014).
Leone, V. et al. Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism. Cell Host Microbe 17, 681–689 (2015).
Thomas, V., Clark, J. & Doré, J. Fecal microbiota analysis: an overview of sample collection methods and sequencing strategies. Future Microbiol. https://doi.org/10.2217/fmb.15.87 (2015).
Poretsky, R., Rodriguez-R, L. M., Luo, C., Tsementzi, D. & Konstantinidis, K. T. Strengths and limitations of 16S rRNA gene amplicon sequencing in revealing temporal microbial community dynamics. PLOS ONE 9, e93827 (2014).
Ranjan, R., Rani, A., Metwally, A., McGee, H. S. & Perkins, D. L. Analysis of the microbiome: advantages of whole genome shotgun versus 16S amplicon sequencing. Biochem. Biophys. Res. Commun. 469, 967–977 (2016).
Youssef, N. et al. Comparison of species richness estimates obtained using nearly complete fragments and simulated pyrosequencing-generated fragments in 16S rRNA gene-based environmental surveys. Appl. Environ. Microbiol. 75, 5227–5236 (2009).
Caporaso, J. G. et al. QIIME allows analysis of high-throughput community sequencing data. Nat. Methods 7, 335–336 (2010).
Schloss, P. D. et al. Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. Appl. Environ. Microbiol. 75, 7537 (2009).
Langille, M. G. I. et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 31, 814 (2013).
Ten Hoopen, P. et al. The metagenomic data life-cycle: standards and best practices. Gigascience 6, 1–11 (2017).
Olson, E. M., Lin, N. U., Krop, I. E. & Winer, E. P. The ethical use of mandatory research biopsies. Nat. Rev. Clin. Oncol. 8, 620–625 (2011).
Peppercorn, J. et al. Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology. J. Clin. Oncol. 28, 2635–2640 (2010).
López-Contreras, B. E. et al. Composition of gut microbiota in obese and normal-weight Mexican school-age children and its association with metabolic traits. Pediatr. Obes. 13, 381–388 (2018).
Dao, M. C. et al. A data integration multi-omics approach to study calorie restriction-induced changes in insulin sensitivity. Front. Physiol. 9, 1958 (2018).
Kayser, B. D. et al. Serum lipidomics reveals early differential effects of gastric bypass compared to banding on phospholipids and sphingolipids independent of differences in weight loss. Int. J. Obes. 41, 917–925 (2017).
Kayser, B. D. et al. Phosphatidylglycerols are induced by gut dysbiosis and inflammation, and favorably modulate adipose tissue remodeling in obesity. FASEB J. 33, 4741–4754 (2019).
Dao, M. C. et al. A data integration multi-omics approach to study calorie restriction-induced changes in insulin sensitivity. Front. Physiol. 9, 1958 (2019).
Wright, E. K. et al. Microbial factors associated with postoperative Crohn’s disease recurrence. J. Crohns Colitis 11, 191–203 (2017).
Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009).
Grattagliano, I. et al. Utility of noninvasive methods for the characterization of nonalcoholic liver steatosis in the family practice. The “VARES” Italian multicenter study. Ann. Hepatol. 12, 70–77 (2013).
The authors wish to thank funding support for research activities in metagenomics in metabolic disorders (including liver diseases); the European Union support via H2020 EPoS (H2020-PHC-2014-634413 to K.C. and C.V.), the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777377 to M.N. and K.C.). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. J.A.-W. and K.C. thank FP7 Metacardis (grant agreement HEALTH-F4-2012-305312) as well as National support from French Investment for the Future (National Agency of Research; F-CRIN FORCE, Metagenopolis and ICAN). J.A.-W. received a grant from Bettencourt Schueller Fondation. M.N. is supported by a personal ZONMW-VIDI grant 2013 [016.146.327]. A.G.H. is supported by the Amsterdam UMC Fellowship grant, a Health Holland TKI-PPP grant and by the Gilead Research scholarship grant. The authors thank T. Swartz for language editing and E. Prifti for critical reading.
M.N. is in the Scientific Advisory Board of Caelus Pharmaceuticals, the Netherlands. K.C. is on the Scientific Advisory Board of LNC therapeutics and CONFO therapeutics and has contract consultancy and contract collaboration with Danone Research. None of these are directly relevant to the current paper. There are no patents, products in development or marketed products to declare. The other authors declare no competing financial interests.
Peer review information
Nature Reviews Gastroenterology & Hepatology thanks A. Alisi, A. Mardinoglu, R. Reimer and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- Shotgun sequencing
Involves randomly breaking up DNA sequences into lots of small segments, which are further sequenced to obtain reads; computational programmes then reassemble the sequence by looking for regions of overlap.
- Faecal microbiota transplantation
(FMT). Transfer of faeces from a donor to a receiver to obtain a beneficial clinical outcome by modifying the recipient’s gut microbiota.
- Non-alcoholic fatty liver disease
(NAFLD). A liver disease characterized by pathological hepatic fat accumulation from simple steatosis to non-alcoholic steatohepatitis.
- Non-alcoholic steatohepatitis
(NASH). A severe stage of NAFLD characterized by steatosis, hepatocyte ballooning (that is, cell injury) and inflammation, which can be associated with and/or evolve to fibrosis, cirrhosis and hepatocellular carcinoma.
Corresponds to intrahepatic fat of at least 5% of liver weight, which can be reversible upon lifestyle modifications.
- Liver fibrosis
The excessive accumulation of extracellular matrix proteins, including collagen, that occurs in most chronic liver aetiologies.
Corresponds to the histological development of regenerative nodules surrounded by fibrous bands in response to chronic liver injury.
- Compensated cirrhosis
Occurs when the liver is at the stage of severe fibrosis yet can still perform its basic functions; thus, compensated cirrhosis is not associated with specific clinical symptoms.
- Decompensated cirrhosis
Occurs when the liver is at the stage of severe fibrosis and liver dysfunction, leading to clinical symptoms such as internal bleeding, ascites and hepatic encephalopathy.
- Gynoid distribution
Refers to the body fat that is preferentially placed around the hip.
About this article
Cite this article
Aron-Wisnewsky, J., Vigliotti, C., Witjes, J. et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 17, 279–297 (2020). https://doi.org/10.1038/s41575-020-0269-9
This article is cited by
Effects of exercise on high-fat diet–induced non-alcoholic fatty liver disease and lipid metabolism in ApoE knockout mice
Nutrition & Metabolism (2022)
Helicobacter pylori infection is not an independent risk factor of non-alcoholic fatty liver disease in China
BMC Gastroenterology (2022)
Nature Reviews Gastroenterology & Hepatology (2022)
Signal Transduction and Targeted Therapy (2022)
European Journal of Clinical Nutrition (2022)